| COVID-19 Vaccine |
1 |
0.94 |
| T-Lymphocyte |
0 |
0.88 |
| Biologic Therapy |
0 |
0.81 |
| Vaccines |
0 |
0.78 |
| Influenza |
0 |
0.66 |
| Pneumonia |
0 |
0.59 |
| Patient Safety |
0 |
0.51 |
| COVID-19 |
0 |
0.49 |
| Influenza Vaccine |
0 |
0.19 |
| Psoriasis |
0 |
0.17 |
| Immunization |
0 |
0.16 |
| Immunocompromise |
0 |
0.16 |
| Memory |
0 |
0.16 |
| Severe Acute Respiratory Syndrome (SARS) |
0 |
0.16 |
| Interleukin-2 |
0 |
0.14 |
| Rheumatoid Arthritis |
0 |
0.12 |
| Acute Respiratory Distress Syndrome |
0 |
0.11 |
| Adverse Effects |
0 |
0.08 |
| Arthritis |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Fatigue |
0 |
0.08 |
| Immunology |
0 |
0.08 |
| Interleukin |
0 |
0.08 |
| Isolation |
0 |
0.08 |
| Match |
0 |
0.08 |
| Microbiology |
0 |
0.08 |
| NHS |
0 |
0.08 |
| Outpatient Clinic |
0 |
0.08 |
| Pain |
0 |
0.08 |
| Plasma |
0 |
0.08 |
| Pneumococcal Vaccine |
0 |
0.08 |
| Salary and Compensation |
0 |
0.08 |
| Tumor |
0 |
0.08 |
| Headache |
0 |
0.06 |
| Health Care Reform |
0 |
0.06 |
| Microbiome |
0 |
0.06 |
| Pain Management |
0 |
0.06 |
| Revenue and Practice Management |
0 |
0.06 |